trivago N.V.: Dr. Joana Carena Breidenbach, Acquisition
trivago disclosed an employee-program-linked derivative acquisition by board member Dr. Joana Carena Breidenbach with a reported volume of 10,500 EUR.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
trivago (TRVG) reported an acquisition of derivatives by supervisory board member Dr. Joana Carena Breidenbach on 10 August 2026.
The transaction involves a derivative instrument with ISIN US89686D3035, executed on Nasdaq (MIC: XNAS). The nature of the transaction is classified as an acquisition linked to an employee share participation programme, and it is an initial notification under manager transaction rules.
The reported price is 0.30 EUR per instrument, with an aggregated transaction volume of 10,500 EUR. The issuer is identified as trivago N.V. with LEI 391200MJ56OU7D3JM080, and the notification is made as a regulatory disclosure of dealings by a person discharging managerial responsibilities.
News Explained
The derivative’s ownership effect is unspecified, while separate records show the director’s recent activity was net selling.
The trivago disclosure records Dr. Joana Carena Breidenbach’s
The supplied 90-day insider record shows two sales by Breidenbach totaling 37,733 shares and no purchases, making the broader recorded activity net selling.
Details
News Market Reaction – TRVG
On Sep 8, the first trading day after this news, TRVG closed 2.84% below the previous close. Argus tracked a trough of -2.3% from its starting point during tracking. Our momentum scanner recorded 10 alerts in the available session data.
Data tracked by StockTitan Argus for the Sep 8 session.
Key Figures
- Transaction Price
- 0.30 EUR
- Option-linked acquisition
- Transaction Volume
- 10,500 EUR
- Option-linked acquisition
- Transaction Date
- 10.08.2026
- Acquisition notification
Historical Context
-
Revenue growth and raised guidance were followed by a 2.45% decline.
-
Second-quarter results scheduling was followed by a 1.1% decline.
-
ADR trading resumed on German exchanges, followed by a 4.59% gain.
-
First-quarter growth and improved guidance coincided with a 10.76% gain.
-
The antitrust damages claim was followed by a 10.76% gain.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
derivative financial
isin financial
lei regulatory
persons discharging managerial responsibilities regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
trivago N.V.: Dr. Joana Carena Breidenbach, Acquisition
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them,
04. Sep 2026 / 22:00 CET/CEST, transmitted by GlobeNewswire.
The issuer is solely responsible for the content of this announcement.
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name
| Title | Dr. |
| First name | Joana Carena |
| Last name | Breidenbach |
2. Reason for the notification
a) Position / status
| Member of the administrative or supervisory body |
b) Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
| trivago N.V. |
b) LEI
| 391200MJ56OU7D3JM080 |
4. Details of the transaction(s)
a) Description of the financial instrument
| Type | Derivative |
| ISIN | US89686D3035 |
b) Nature of the transaction
| Acquisition |
| Transaction linked to the exercise of a share option programme | Transaction under an employee share participation programme |
c) Price(s) and volume(s)
| Price(s) | Volume(s) |
|---|---|
| 0.30 EUR | 10,500 EUR |
d) Aggregated information
| Price | Aggregated volume |
|---|---|
| 0.30 EUR | 10,500 EUR |
e) Date of the transaction (CET/CEST)
| 10.08.2026 |
f) Place of the transaction
| Name | Nasdaq |
| MIC | XNAS |
End of message
GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.
Archive at www.globenewswire.com
| Language | English |
| Company | trivago N.V. |
| Kesselstraße 5 – 7 | |
| 40221 Düsseldorf | |
| Germany | |
| Internet | https://www.trivago.com/ |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction involving TRVG did Dr. Joana Carena Breidenbach report?
Dr. Joana Carena Breidenbach, a member of trivago’s administrative or supervisory body, reported an acquisition of a derivative related to trivago (TRVG). The transaction is linked to an employee share participation programme and constitutes an initial notification under manager transaction regulations.
What were the price and volume of Dr. Breidenbach’s TRVG derivative acquisition?
The reported transaction price for the trivago-related derivative was 0.30 EUR, with an aggregated transaction volume of 10,500 EUR. These figures reflect the total value disclosed for the acquisition in the regulatory notification.
When and where was the TRVG insider transaction by Dr. Breidenbach executed?
The transaction by Dr. Joana Carena Breidenbach was executed on 10 August 2026 and took place on Nasdaq, identified by market identifier code XNAS. This timing and venue are specified in the regulatory disclosure of the deal.
What type of financial instrument did Dr. Breidenbach acquire in relation to TRVG?
The financial instrument acquired is classified as a derivative tied to trivago (TRVG), with ISIN US89686D3035. The company states that the transaction is under an employee share participation programme, indicating it is part of a structured employee-related scheme.
How is trivago N.V. identified in the insider transaction disclosure for TRVG?
In the disclosure, the issuer is trivago N.V., identified with the legal entity identifier 391200MJ56OU7D3JM080. This identification confirms the company whose instruments are subject to the reported derivative acquisition by Dr. Joana Carena Breidenbach.